FindTrial
Sign In

Cross sectional study of HER2 and PD-L1 expression in ovarian carcinoma

HER2 AND PD-L1 expression in ovarian carcinoma: An immunohistochemical study with insights into tumor immune microenvironment- A three-year cross-sectional study at SMHRC tertiary care hospital, Nagpur. - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/111266
Enrollment
45
Registered
2026-05-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N838- Other noninflammatory disorders ofovary, fallopian tube and broad ligament

Interventions

Intervention1: Nil: Nil

Sponsors

Neha Vishnu Misal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Histopathologically confirmed cases of primary ovarian carcinoma. 2.The availability of adequate formalin-fixed and paraffin embedded (FFPE) tissue blocks. 3.Complete clinicopathological data (age, clinical history, tumor grade/stage) 4.Prospective and retrospective cases.

Exclusion criteria

Exclusion criteria: 1.Metastatic or secondary tumors involving the ovary. 2.Recurrent ovarian tumors or cases treated with prior chemotherapy or radiotherapy. 3.Poorly preserved or inadequate tissue samples for immunohistochemistry. 4.All those cases that have undergone incisional biopsy, excisional biopsy, trucut biopsy, mastectomy.

Design outcomes

Primary

MeasureTime frame
To determine the expression of HER2 and PD-L1 in epithelial ovarian carcinoma by immunohistochemistryTimepoint: after 1 week—

Secondary

MeasureTime frame
To correlate HER2 expression with histopathological subtype, tumor grade and stageTimepoint: Baseline—

Countries

India

Contacts

Public ContactNeha Vishnu Misal

Datta Meghe Medical College, Nagpur

sms14587@gmail.com9403599622

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026